Pune, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The global influenza medication market size is projected to reach USD 993.7 million by 2026, exhibiting a CAGR of 2.2% during the forecast period. Increasing global burden of influenza will be one of the central forces driving the growth of this market. Influenza, or the flu, is a virus that infects the human respiratory system, that is, the throat, lungs, and nose. Usually, the infection subsides on its own, but sometimes it can turn severe and even prove to be fatal.

According to the World Health Organization (WHO), every year influenza epidemics around the globe affect around 3 million to 5 million people and cause respiratory deaths between 290,000 and 650,000. The developed nations are also bearing the impact of this deadly virus. For instance, the US Centers for Disease Control and Prevention (CDC) states that since 2010, the occurrence of influenza-related illnesses in the US have been between 9 million and 45 million.

In 2016-17, the CDC estimates that hospitalizations resulting from influenza alone will be around 500,000.  Thus, such exponential rise in the prevalence of this infection will raise the influenza treatment market demand in the coming years.

Fortune Business Insights™ states that the value of this market stood at USD 889.2 million in 2018. The report also contains:

  • Exhaustive research into the different market segments;
  • Comprehensive assessment of the various drivers and challenges influencing the market;
  • 360-degree analysis of the competitive landscape (company profiles, strategies, and product offerings); and
  • Careful study of the regional dynamics shaping the market.


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/influenza-medication-market-101843


INDUSTRY DEVELOPMENT:

  • October 2019: Genentech, Inc. announced the FDA approval of Xofluza (Baloxavir Marboxil) for individuals at an elevated risk of developing influenza-related complications.
  • October 2019: Shionogi & Co., Ltd. announced the filing of a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) in Japan for the postexposure prophylaxis of influenza virus infection.
  • August 2019: Shionogi & Co., Ltd. announced the approval of Xofluza (Baloxavir Marboxil) 20mg tablets for the treatment of influenza types A and B in patients over the age of 12 in Taiwan.


To get to know more about the short-term & long-term impact of COVID-19 on this market, please click here: https://www.fortunebusinessinsights.com/industry-reports/influenza-medication-market-101843


Rising Threat from Risk Factors for Influenza to Propel the Market

Prominent among the influenza medication market trends is the threats posed by the risk factors inducing or worsening the effects of influenza infection in humans. According to the CDC, the people most at risk for flu complications include pregnant women, diabetics, asthmatics, adults aged 65 or older, young children, HIV/AIDS patients, cancer patients, and people suffering from chronic lung or heart condition. For example, congestive heart condition in a person can worsen if she contracts the flu infection.

The influenza drugs market growth is further bolstered by the rising prevalence of these risk factors. For instance, the WHO estimates that approximately 235 million people worldwide are living with asthma currently, while 18.1 million new cancer cases were reported worldwide in 2018, the WHO states.   

Strong Support to R&D Activities to Fuel the Market in North America

North America is anticipated to dominate the influenza medication market share in the forecast period as the region generated a revenue of USD 527.3 million in 2018. Financial and regulatory support to academic institutions and private companies for R&D for studying influenza virus mutations will be the primary growth factor for the market in the region. Other than this, high incidence of different types of influenza along with rising awareness about the disease will also expand the regional market.

Government initiatives, increasing disposable income, and growing awareness about the dangers of the infection will accelerate the influenza medication market revenue in Asia-Pacific. In Europe, influenza research is gathering momentum which is driving the market in the region, while in the Middle East and Africa, availability of subsidized drugs will augment the market.


Quick Buy -  Influenza Medication Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101843


Regulatory Support to Novel Therapies to Fire up Competition

Major players in this market are intensely engaged in developing new and unique therapies for influenza and regulatory authorities are providing the necessary support to the efforts, according to one of our leading analysts. Not only is this widening consumer choice, but it is also enhancing the market potential, as per the influenza medication market analysis.


Key Players Covered in the Influenza Medication Market Report:

•          Alvogen

•          Amneal Pharmaceuticals LLC

•          Teva Pharmaceutical Industries Ltd.

•          GlaxoSmithKline plc

•          Seqirus (CSL)

•          Genentech, Inc.

•          Macleods Pharmaceuticals Ltd.

•          Zydus Pharmaceuticals, Inc. (Zydus Cadila)

•          Lupin Limited

•          BIOCRYST PHARMACEUTICALS, INC.

•          Shionogi & Co., Ltd.


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/influenza-medication-market-101843


Influenza Medication Market Segmentations:

By Treatment

•          Baloxavir marboxil

•          Oseltamivir phosphate

•          Others

By Influenza Type

•          Influenza A

•          Influenza B

By Route of Administration

•          Oral

•          Others

By Distribution Channel

•          Hospital Pharmacies

•          Retail Pharmacies

•          Online Pharmacies

•          Others

By Geography

•          North America (U.S. and Canada)

•          Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

•          Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)

•          Latin America (Brazil, Mexico, and Rest of Latin America)

•          Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


SECONDARY DATA SOURCES THAT WE REFER TO:

  • Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market
  • Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.
  • Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics
  • Industry journals and paid databases

SECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:

  • Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies
  • Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.
  • Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility
  • Number of procedures and average price of procedures
  • Replacement rate and pricing of capital equipment
  • Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities
  • Market & technological trends, new product developments, product pipeline.


Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/influenza-medication-market-101843


Have a Look at Related Reports:

Influenza Vaccine Market Share & Industry Analysis, By Type (Inactivated and Live Attenuated), By Valency (Quadrivalent and Trivalent), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Geography Forecast, 2019-2026

Autotransfusion Devices Market Share & Industry Analysis, By Product Type (Autotransfusion Systems and Consumables & Accessories) By Application (Cardiovascular Surgeries, Orthopedic Surgeries, Neurological Surgeries, Obstetrics & Gynecological Surgeries, and Others) By End User (Hospitals and Specialty Clinics & Others) and Regional Forecast, 2019-2026

Vaccines Market Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026

Hiv/Aids Drugs Market Share and Global Trend By Drug Class (Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Integrase Inhibitors, Combination HIV Medicines, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Geography Forecast Till 2026

Hepatitis C Drug Market Share & Industry Analysis, By Product (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), By Disease Type (Acute Hepatitis C, Chronic Hepatitis C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2019-2026


About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.


Contact Us:

Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs


Press Release: https://www.fortunebusinessinsights.com/press-release/influenza-medication-market-9563